-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$35.6731.58% Upside
ArriVent BioPharma, Inc. Common Stock Frequently Asked Questions
-
What analysts cover ArriVent BioPharma, Inc. Common Stock?
ArriVent BioPharma, Inc. Common Stock has been rated by research analysts at Citigroup, H.C. Wainwright, Oppenheimer in the past 90 days.